Minimal Residual Disease Market Trend

Increasing number of cancer patients, technological advancements in the field of minimal residual disease and increased R&D spending are some of the major factors propelling the minimal residual disease market globally. Furthermore, technological developments in diagnostics and therapeutics is also one of the factor propelling the growth of minimal residual disease market. However, high cost of minimal residual disease testing kits is one of the major factor expected to hamper the global growth of the market.

Minimal Residual Disease Market Segmentation

The Minimal Residual Disease market is segmented by Product, Technology, Application, End User and geography. The Products studied in the report are Assay Kits & Reagents and Instruments. Furthermore, Technology segment is further bifurcated into Polymerase Chain Reaction, Next-Generation Sequencing, Flow Cytometry and Other Technologies. Likewise, the Application is sub-segmented into Hematological Malignancies (Leukemia and Lymphoma), Solid Tumors, Multiple Myeloma and Other Application. Moreover, various End Users studied in this report are Hospitals & Specialty Clinics, Diagnostics Laboratories, Academic & Research Institutes and Other End Users. Based on Geography, the minimal residual disease market is studied across the countries of key regions such as, North America, Europe, Asia Pacific and RoW.

Minimal Residual Disease Market by Geography

Based on geography, the minimal residual disease market is studied across the countries of key regions such as, North America, Europe, Asia Pacific and RoW. Among all the regions, the North America is anticipated to hold the major share of the global minimal residual disease market. Major drivers include growing various technological advancements, the presence of major players, expansion of the healthcare sector and large number of clinical studies being done for MRD testing nationwide.

Minimal Residual Disease Market Report Key Benefits

• The report offers changing market dynamics in the Minimal Residual Disease market, presenting historical, current and projected market size in terms of value (USD Million)

• The report comprises a detailed analysis of the factors that drive and restrict the growth of global Minimal Residual Disease market.

• The research study provides an in-depth analysis of the industry value chain focusing on the peer and parent markets of Minimal Residual Disease

• It presents a comprehensive assessment of geographical regions exhibiting promising growth, potential and niche segments, and a neutral perspective on the Minimal Residual Disease market performance

• Key players within the global Minimal Residual Disease market are profiled to understand the competitor scenario

Minimal Residual Disease Market Key Players

Some of the major players operating in the global minimal residual disease market includes F. Hoffmann-la Roche AG, Laboratory Corporation of America Holdings, Guardant Health, Inc., Sysmex Corporation, Neogenomics Laboratories, Molecularmd (A Subsidiary of Icon PLC), Adaptive Biotechnologies, Archerdx (Invitae Corporation), Bio-Rad Laboratories, Inc., Natera, Inc., Opko Health, Inc., Genetron Health, Quest Diagnostics, Inc. and others.

INFOGRAPHICS

Research Objectives of Minimal Residual Disease Market Report